Browsing by Author DE JONG Marion

Showing results 1 to 11 of 11
Publication YearJRC N°TitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2017JRC99096213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer XenograftsNONNEKENS J; CHATALIC K.l.s.; MOLKENBOER- KUENEN Jannike; BEERENS Cecile; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; VELDHOVEN-ZWEISTRA Joke; SCHOTTELIUS Margret; WESTER Hans-Jürgen; VAN GENT D, et alArticles in periodicals and books
2016JRC100346213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancerCHATALIC K.l.s.; NONNEKENS J; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SCHOTTELIUS Margret; WESTER Hans-Jürgen; VAN WEERDEN W.m.; BOERMAN Otto; DE JONG Marion; HESKAMP SandraArticles in periodicals and books
2013JRC81168High Resolution microSPECT imaging of Bi-213DE SWART J; SEGBERS M; MORGENSTERN Alfred; VAN DER HAVE F; CHAN Ho-Sze; BERNDSEN S.c.; BRUCHERTSEIFER Frank; DE JONG Marion; BEEKMAN F.j.; KONIJNENBERG M.w.Articles in periodicals and books
2014JRC90200Influence of tumour size on targeted alpha therapy with 213Bi-[DOTA,Tyr3]octreotate (DOTA-TATE) in a small cell lung carcinoma (SCLC) mouse model.CHAN Ho-Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG MarionArticles in periodicals and books
2016JRC100045Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotateCHAN Ho Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; BAUM Richard; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG MarionArticles in periodicals and books
2015JRC96963The next step in increasing the efficacy of PRRT: Preclinical studies in vicvo and in vitro with 213Bi-[DOTA0,Tyr3]-octreotateCHAN Ho Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; ANDERSON Tamara; NYSUS Monique; BREEMAN W.a.p.; ATCHER Robert; MORGENSTERN Alfred; BRUCHERTSEIFER Frank, et alArticles in periodicals and books
2014JRC88671Optimizing energy window settings for microSPECT of 213BiDE SWART J; SEGBERS M; CHAN Ho-Sze; MORGENSTERN Alfred; KOELEWIJN S.j.; BRUCHERTSEIFER Frank; DE JONG Marion; BEEKMAN F.j.; KONIJNENBERG M.w.Articles in periodicals and books
2014JRC88669Optimizing labeling conditions of 213Bi somatostatin analogues for receptor mediated process in preclinical modelsCHAN Ho-Sze; DE BLOIS Erik; KONIJNENBERG M.w.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG MarionArticles in periodicals and books
2016JRC101798Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyCHAN Ho Sze; DE BLOIS Erik; KONIJNENBERG M.w.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; NORENBERG Jeffrey; VERZIJLBERGEN Fred J; DE JONG Marion; BREEMAN WouterArticles in periodicals and books
2015JRC96382Targeted Alpha Radionuclide Therapy of Prostate Cancer Using a Small Molecule Inhibitor of Prostate-specific Membrane Antigen (PSMA)CHATALIC K.l.s.; HESKAMP Sandra; NONNEKENS J; MOLKENBOER-KUENEN J.d.m.; VAN GENT D; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; WEINEISEN M.; WESTER Hans-Jürgen; VAN WEERDEN W.m., et alArticles in periodicals and books
2016JRC98414Utilizing High-Energy γ-Photons for High-Resolution 213Bi SPECT in MiceDE SWART J; CHAN Ho Sze; GOORDEN Marlies; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BEEKMAN F.j.; DE JONG Marion; KONIJNENBERG M.w.Articles in periodicals and books